Exchange Traded Concepts Boosts Gilead Sciences Stake

Investment firm increases position in biopharmaceutical company by nearly 46% in Q4

Mar. 28, 2026 at 8:36am

Got story updates? Submit your updates here. ›

Exchange Traded Concepts LLC, an investment management firm, increased its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 45.7% during the fourth quarter of 2025, according to a recent SEC filing. The fund now owns 243,532 shares of the biopharmaceutical company's stock, valued at $29.9 million.

Why it matters

Gilead Sciences is a major player in the pharmaceutical industry, known for its antiviral therapies for HIV and viral hepatitis. The increase in Exchange Traded Concepts' position suggests the firm sees growth potential in Gilead's business and stock performance.

The details

According to the filing, Exchange Traded Concepts purchased an additional 76,432 shares of Gilead Sciences during the fourth quarter. This brings the firm's total holdings in the company to 243,532 shares. The increased position reflects Exchange Traded Concepts' confidence in Gilead's future prospects.

  • Exchange Traded Concepts filed the report disclosing the position increase on March 28, 2026.
  • The position change occurred during the fourth quarter of 2025.

The players

Exchange Traded Concepts LLC

An investment management firm that increased its stake in Gilead Sciences, Inc.

Gilead Sciences, Inc.

A biopharmaceutical company focused on developing antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Exchange Traded Concepts in Gilead Sciences suggests the firm sees long-term growth potential in the biopharmaceutical company's product pipeline and market position. This could signal positive sentiment among institutional investors regarding Gilead's future performance.